Emcure Pharmaceuticals Ltd on Tuesday reported a 29.31 per cent increase in consolidated net profit to Rs 325.06 crore during the September quarter helped by a strong growth in international business.The pharma company had posted a profit of Rs 251.37 crore in the year-ago period, it said in a regulatory filing.Its revenue from operations rose to Rs 2,820.47 crore during the September quarter, up from Rs 2,269.82 crore a year earlier.Its total expenses were higher at Rs 2,377.87 crore during the quarter under review, up from Rs 1,931.52 crore a year ago, as per the filing.The company recorded a strong 34 per cent growth in international business to Rs 1,665.2 crore during the quarter while its domestic business rose 11.1 per cent to Rs 1,155.3 crore, according to a statement.Live EventsIn its international business, Europe grew 36 per cent, Canada was up 24 per cent, while in the rest of the world markets, it showed a growth of 41.1 per cent, as per the statement.During the April-September period (H1), the company posted a profit of Rs 617.56 crore, 32.47 per cent higher than Rs 466.16 crore in the year-ago period.Emcure Pharmaceuticals Chairman, Managing Director and CEO Satish Mehta said, "Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings....
We expect business momentum to sustain into H2FY27."The shares of Emcure Pharmaceuticals settled 5.31per cent higher at Rs 1982.55 apiece on the BSE.(You can now subscribe to our ETMarkets WhatsApp channel)
